FDA expands Pluvicto label, making it available to most metastatic prostate cancer patients
The FDA approved Novartis’ radiopharma drug Pluvicto for use alongside hormone therapy, making the drug available to many more patients. The approval nearly doubles the eligible patient population for Pluvicto, according to a Novartis
August 3, 2026 11:26 AM EDT PharmaFDA+ FDA expands Pluvicto label, making it available to most metastatic prostate cancer patients Lei Lei Wu News Reporter The FDA approved Novartis’ radiopharma drug Pluvicto for use alongside hormone therapy, making the drug available to many more patients. The approval nearly doubles the … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that